Title |
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
|
---|---|
Published in |
Journal of Neuroinflammation, October 2011
|
DOI | 10.1186/1742-2094-8-146 |
Pubmed ID | |
Authors |
Klaus Lehmann-Horn, Eva Schleich, Deetje Hertzenberg, Alexander Hapfelmeier, Tania Kümpfel, Nikolas von Bubnoff, Reinhard Hohlfeld, Achim Berthele, Bernhard Hemmer, Martin S Weber |
Abstract |
Clinical trials evaluating anti-CD20-mediated B-cell depletion in multiple sclerosis (MS) and neuromyelitis optica (NMO) generated encouraging results. Our recent studies in the MS model experimental autoimmune encephalomyelitis (EAE) attributed clinical benefit to extinction of activated B-cells, but cautioned that depletion of naïve B-cells may be undesirable. We elucidated the regulatory role of un-activated B-cells in EAE and investigated whether anti-CD20 may collaterally diminish regulatory B-cell properties in treatment of neuroimmunological disorders. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 1% |
Unknown | 91 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 18 | 20% |
Researcher | 16 | 17% |
Student > Bachelor | 9 | 10% |
Student > Master | 7 | 8% |
Student > Postgraduate | 6 | 7% |
Other | 15 | 16% |
Unknown | 21 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 25% |
Neuroscience | 15 | 16% |
Agricultural and Biological Sciences | 10 | 11% |
Biochemistry, Genetics and Molecular Biology | 8 | 9% |
Immunology and Microbiology | 4 | 4% |
Other | 8 | 9% |
Unknown | 24 | 26% |